Valeant Pharmaceuticals says it's ready to up the ante in its hostile takeover bid for Allergan.
Abbott says it will go ahead with its plan to deal its generic pharmaceuticals line to Mylan for $5.3 billion and reports 3rd-quarter sales in line with expectations.
Get the complete picture with a MassDevice Plus membership. Registered users can login here.
Valeant Pharmaceuticals says it might up the ante in its hostile takeover bid for Allergan as it reports higher-than-forecast profits for its 3rd quarter.
Actavis aims to head Valeant Pharmaceuticals off at the pass with a competing bid to acquire Allergan, people familiar with the matter tell Reuters.
Baxter International confirmed Cambridge, Mass., as the new R&D hub for Baxalta, the planned spinout of its biopharmaceuticals business.
Pharmaceutical companies have slashed sales staffs in favor of key account reps amid a drastic decline in access to physicians.
Image courtesy ZS Associates. Click to enlarge
Allergan is still looking to prevent Valeant Pharmaceuticals and Pershing Square from voting their shares in a December 18 shareholder meeting the company was forced to host.
Need Medtech news in a minute? We Deliver!
MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.
News and information for the medical device industry and the companies that drive it. Learn the latest about sales, jobs, legislation and other areas of the medtech industry.